CMS

  • |

    The Drug Pricing Rule Has a Lobbyist in the Back Seat

    ByPhil McCracken

    I look at Washington’s healthcare paperwork the way a diner waitress looks at a fake coupon: polite, tired, and already hunting for the fine print. CMS is considering a proposed Medicare rule that could treat certain fixed-combination drugs as the same qualifying single-source drug as an originator medicine for price negotiation. Patients may see one prescription. The policy question is whether Washington sees one product—or several convenient identities parked under the same hood.

    CMS issued the proposal June 12, set an August 17 comment deadline, and is expected to finalize it in fall 2026. That makes this less a chemistry quiz than a money-trail dispute. If a combination product remains legally separate from the medicine it combines, more revenue could remain outside the negotiation process. That is not proof anyone designed the product as an escape hatch. It is the practical question sitting on the counter while everyone argues about labels.

    Inside Health Policy reported that biologics manufacturers objected to CMS’s approach, arguing that separate FDA categories raise legal-authority and innovation concerns. Those are serious arguments, and agencies should not smuggle major policy changes through a filing cabinet labeled “technical clarification.” But the industry’s preferred separation also has a financial consequence: separate categories can mean separate treatment when Medicare decides what qualifies for negotiation.

    This is where the fine print starts wearing donor perfume. The public argument is about innovation, regulatory boundaries, and whether CMS has gone too far. The money question is simpler: who benefits if the category stays split? Manufacturers may preserve separate revenue streams from negotiated pricing, while patients and taxpayers are left to admire the elegance of the classification system from the payment window.

    At the pharmacy drive-through, nobody orders “one originator medicine with a regulatory garnish.” They get a prescription. In Washington, however, one prescription can be asked to produce two billing identities, two receipts, and two opportunities to keep the negotiated-price window closed. The rule is still proposed, the dispute is still active, and the invoice has not finished crawling out from under the lobbyist’s coat. But the public should know what this technical fight can decide: whether a medicine’s category serves patients—or protects the revenue attached to it.

    Sources

  • |

    When Efficiency Locks the Front Door

    ByHarlan Quill

    I ran the arithmetic on the Biden-Harris plan to expand home-based care versus the Trump policy freeze described around CMS, and the numbers have a familiar county-office quality: fewer new providers may look tidy on paper, but a locked door is not an appointment. Supporting family caregivers, improving care jobs, and helping seniors remain independent all require actual capacity—not merely a promise that capacity would be nice.

    Fraud prevention matters. So does not confusing “fewer entrants” with “better access.” If legitimate home-health agencies and hospice providers cannot get through the front door, seniors wait, families absorb another unpaid shift, and care workers are asked to perform fiscal miracles before lunch. The spreadsheet may show fewer bad actors. It also shows a locked door, and the person outside still needs a caregiver.

  • |

    Seniors Need Care at Home—Not a Nationwide Freeze: Existing Providers Stay, New Providers Stop

    ByMoses Pray

    “Help seniors stay at home” gets a choir seat on the Biden-Harris side: expand home & community care, support caregivers, strengthen care-worker pay. Then the Trump CMS side clears its throat with the paperwork plan: a 6-month nationwide freeze, new home health enrollments blocked, new hospice enrollments blocked—while the banner insists on the comforting contradiction: existing providers stay. New providers stop.

    Here’s the moral audit: bureaucracy calls it compassion because seniors can “stay at home.” Families hear the real deal—no new providers means the waiting room migrates into the living room. Mercy delayed by forms is still mercy delayed, and somebody always gets to repeat the slogan while other people run out of options.

  • |

    The Stroke Code That Needed A Receipt

    ByHugh Jass

    The document coughed, and out came the familiar Medicare Advantage ghost story: CMS auditors looking at an HHS-OIG oversight item found overpayment concerns tied to serious diagnosis codes that were not supported by the medical records. Not patients. Not bedside judgment. The target here is the risk-coding machine, where a diagnosis can enter the payment bloodstream with federal seriousness, then become shy when someone asks where it lives in the folder.

    This is the bureaucracy’s finest magic trick: crisp enough to affect payment, foggy enough to need a lantern. In public-records terms, if a diagnosis code is sturdy enough to help bill the government, it should be sturdy enough to stand upright when the file drawer opens. Otherwise, we are not doing health oversight. We are conducting a séance for a receipt.

  • |

    When a Virtual Check‑In Feels Like a Paperwork Excuse: OIG Unearths $2.26 Million in Sketchy Remote Visits

    ByHugh Jass

    In an April 23, 2026 audit from the Office of Inspector General (OIG), a long-hidden bureaucratic gem emerged—approximately $2.26 million in potentially improper Medicare payments for virtual check-ins and e-visits. Reading like the diary nobody locked, this audit finds that something was amiss in the virtual halls of healthcare billing.

    This isn’t just about imaginary band-aids on imagined cuts. It’s about weaknesses in oversight that allowed these virtual care payments to balloon into multimillion-dollar windfalls, all while CMS was haunted by gaps in system edits and provider education. The very nature of paperwork itself stands accused of duplicity.

    The OIG report breaks it down: around $1.96 million tied to virtual check-ins coincided suspiciously with recent or next-day Evaluation/Management visits. Meanwhile, duplicate billing during e-visits added another $298,200 to the tab. In total, 173,287 services went unnoticed under timelines tighter than a bureaucrat’s grip on their favorite pen.

    No, it’s not fraud; we’re talking ‘potentially improper’—a distinction as sharp and necessary as the label on a mystery envelope that says, ‘Do Not Open.’ The blame lies partly with missing system edits in CMS and the MACs, compounded by bewildered providers deciphering modifiers like an undecided jury.

    The Office of Inspector General, with the calm gravitas of a librarian discovering a hidden annex, offered a roadmap: implement system edits (which CMS accepted), fortify code descriptions (less enthusiasm there), and bolster provider education (agreed upon with the eagerness of a clerk discovering extra forms to file).

    So why should this matter? Because it’s taxpayer money squirming away through administrative fissures. The report’s findings underscore just how bizarrely captivating paperwork can be—we don’t always see the full story unless someone turns on the filing cabinet’s lamp.

    Remember: this isn’t just a tale of fiscal oversight missing a beat. It’s about the modifiers that walked in wearing suspiciously innocent labels, revealing a system that promises future improvements. Yet, even as edits loom, expect the receipts to keep sweating.

    Sources

End of content

End of content